- •
Clinical manifestations in a patient with persistent hypereosinophilia may be related to underlying disease, organ damage and dysfunction provoked by eosinophils, or both. Pathologic assessment is key to establishing a direct role for eosinophils in signs and symptoms, thereby defining a hypereosinophilic syndrome.
- •
Most patients presenting with hypereosinophilia have an underlying disease or condition driving polyclonal eosinophil expansion. Many of these conditions are treatable, and the causal
Management of Hypereosinophilic Syndromes
Section snippets
Key points
Assessment for the presence of eosinophil-mediated complications
Activated eosinophils are prone to infiltrate various tissues and release a wide array of mediators, inducing organ or system damage and dysfunction, as developed in detail by Weller and Akuthota elsewhere in this issue. According to the currently accepted definition, diagnosis of a HES can be proposed in the presence of documented persistent HE (ie, in routine practice: [1] blood eosinophil count greater than 1.5 × 109/L on at least 2 occasions, ideally at minimum 1 month apart, and/or [2]
Diagnostic evaluation of hypereosinophilia
The search for an underlying cause of HE, developed in detail by Ogbogu and Curtis elsewhere in this issue, is conducted simultaneously with assessment for eosinophil-mediated damage. In most patients, an underlying disease or condition (eg, drug allergy, parasitic infections, or cancer) is found after clinical examination and a limited series of relatively routine investigations. When these first-line investigations are negative, further testing is warranted. Diagnostic evaluation of HE is
Treatment of hypereosinophilic syndromes associated with a known underlying condition
In most situations where HE is reactive (secondary) and judged deleterious, systemic corticosteroid therapy represents the most effective and rapid means of reducing eosinophils. By contrast, primary HE that can accompany various myeloid neoplasms (including FIP1L1-PDGFRA–associated disease) is typically corticosteroid resistant, and treatment should target the underlying hematologic disorder or cytogenetic abnormality.
Specific management of lymphocytic variant hypereosinophilic syndrome
L-HES is an indolent and benign lymphoproliferative disorder that generally responds to oral corticosteroid therapy.42 However, patients often require second-line agents for corticosteroid-sparing purposes (see Table 2). Interferon-α,42 mepolizumab,43 and cyclosporin A42 are the most effective, and isolated responses to hydroxyurea and alemtuzumab have been reported. Modalities for administering these agents are discussed in the section on idiopathic HES.
It is essential that patients with L-HES
Treatment of symptomatic and unexplained hypereosinophilia
From a practical standpoint, when eosinophil-mediated organ damage or dysfunction occurs in the absence of a detectable cause or condition associated with HE (ie, idiopathic HES, including organ-restricted eosinophilic disorders), eosinophil-targeted treatment is justified to control symptoms, restore vital organ function, and prevent further deterioration with development of irreversible damage. Although controlling eosinophilia is the therapeutic end point, eosinophils need not necessarily be
Summary and future considerations
With the recognition more than 40 years ago that chronic HE could be deleterious and the subsequent identification of pathogenic mechanisms underlying HE in specific disease variants, management of patients has improved significantly, resulting in less morbidity and better survival. However, because most available therapeutic agents for HES deplete eosinophils through nonspecific mechanisms, long-term iatrogenic toxicity and treatment-refractory disease remain subjects of concern. This
References (53)
- et al.
Therapeutic approaches to patients with hypereosinophilic syndromes
Semin Hematol
(2012) L4. Eosinophils: how they contribute to endothelial damage and dysfunction
Presse Med
(2013)- et al.
Brachial artery occlusion secondary to hypereosinophilic syndrome
J Vasc Surg
(2005) - et al.
Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins
J Immunol Methods
(2014) - et al.
DRESS syndrome: part I. Clinical perspectives
J Am Acad Dermatol
(2013) - et al.
Hypereosinophilic syndrome—lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations
Oral Surg Oral Med Oral Pathol Oral Radiol
(2013) - et al.
Lymphocytic variant hypereosinophilic syndromes
Immunol Allergy Clin North Am
(2007) - et al.
Therapeutic management of DRESS: a retrospective study of 38 cases
J Am Acad Dermatol
(2015) - et al.
Churg-Strauss syndrome
Autoimmun Rev
(2015) - et al.
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib
Blood
(2014)
Use of pegylated interferon in hypereosinophilic syndrome
Leuk Res
Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome
Leuk Res
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody
Clin Lymphoma Myeloma Leuk
Clinical management of the hypereosinophilic syndromes
Expert Rev Hematol
Hypereosinophilic syndrome: current approach to diagnosis and treatment
Annu Rev Med
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
J Allergy Clin Immunol
Eosinophilic jejunitis presenting as intractable abdominal pain
Case Rep Gastroenterol
Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues
Gut
Eosinophilia-associated muscle disorders: an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms
J Clin Pathol
Eosinophil granule protein localization in eosinophilic endomyocardial disease
N Engl J Med
The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma
Allergy Asthma Clin Immunol
Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases
Clin Exp Immunol
Eosinophils in vasculitis: characteristics and roles in pathogenesis
Nat Rev Rheumatol
Cardiac manifestation of the hypereosinophilic syndrome: new insights
Clin Res Cardiol
Cerebral arteriolar thromboembolism in idiopathic hypereosinophilic syndrome
Arch Neurol
Cited by (23)
Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization
2023, Annals of Allergy, Asthma and ImmunologyIdiopathic hyperosinophilic syndrome presenting as acute abdomen: A case report
2022, Gastroenterologia y HepatologiaTreatment of eosinophilic and hypereosinophilic disorders
2022, Allergic and Immunologic Diseases: A Practical Guide to the Evaluation, Diagnosis and Management of Allergic and Immunologic DiseasesAcute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome
2018, Respiratory Medicine Case ReportsCitation Excerpt :The goal of the therapy is to mitigate hypereosinophilia mediated organ damage. For patients with idiopathic HES, corticosteroids are the first-line therapy and are effective in producing rapid reductions in the eosinophil count [11], but the maintenance dose and the duration of therapy are different because of individual difference [12,13]. Corticosteroids can inhibit the production of the inflammatory mediators such as eosinophil cationic protein, major essential protein, eosinophil peroxidase and eosinophil-derived neurotoxin, which are thought to cause hypercoagulation [14].
Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia
2017, Annals of Allergy, Asthma and ImmunologyCanadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis
2024, Canadian Journal of Neurological Sciences
Disclosure Statement: F. Roufosse has received consultancy fees from GlaxoSmithKline.